These findings suggested that the DNMT3B‐induced methylation of UQCRH may contribute to renal cancer progression and implicated clinical significance of DNMT inhibitor as a therapeutic option for ccRCC. This evidence concerns the gene UQCRH and nonpapillary renal cell carcinoma.